<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0004903" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Wiedemann-Beckwith syndrome (WBS)</z:e> is a syndrome of excessive growing with a high predisposition to developing embryologic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> within the first years of life </plain></SENT>
<SENT sid="1" pm="."><plain>This risk is evaluated between 7.5 and 10%; it varies with the mechanisms of mutations involved </plain></SENT>
<SENT sid="2" pm="."><plain>These take place in two distinct domains of 11p15, which are under parental printing </plain></SENT>
<SENT sid="3" pm="."><plain>Emerging techniques of cytogenetic and molecular biology now have shown correlations between genotypes and phenotypes, and can identify the 30% of WBS who are especially at risk of developing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>A specific follow-up, integrating the specificity of developing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> of each 11p15 mutations involved, is now proposed to patients with WBS </plain></SENT>
</text></document>